IQV · IQVIA Holdings Inc
Price
Snapshot
50 fields · last close| Market Cap | $42.50B |
| P/E | 30.91 |
| Float | 162.8M |
| Beta | 1.18 |
| Volatility | 29.4% |
| Exchange | NYSE |
| Sector | Life Sciences Tools & Services |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 72.5 |
| Price | 258.21 |
| Change | +0.00% |
| Prev Close | 258.21 |
| Open | 260.70 |
| Day Low | 257.07 |
| Day High | 261.98 |
| Avg Vol | 1 |
| Avg $ Vol | $365.6M |
| 52W High | 277.40 |
| 52W Low | 154.50 |
| 52W Pos | 84.4% |
| From High | −6.92% |
| From Low | +67.13% |
| Max DD 1Y | −35.87% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −3.00% |
| SMA 50 | +1.74% |
| SMA 200 | +25.45% |
| RSI (14) | 45.3 |
| Vol 30D | 23.3% |
| Vol 90D | 41.0% |
| 1Y Range | 154–277 |
| Daily bars | 526 |
| Perf Week | −4.50% |
| Perf Month | −2.13% |
| Perf Quarter | +25.36% |
| Perf Half Y | +49.03% |
| Perf Year | +26.70% |
| Perf YTD | +14.57% |
| Prev Day | +0.00% |
| Clavix | B |
| Debt / Eq | 1.58 |
| Curr Ratio | 0.75 |
| Int Cover | 3.2× |
| FCF Margin | 16.3% |
| Rev Growth | +5.9% |
| Profit | Profitable |
| Leverage | High |
| Sector rank | 11 / 19 |
What IQV does
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific.
It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.
This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level.
The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services.
The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services.
It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development.
The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017.
IQVIA Holdings Inc. is based in Durham, North Carolina.
Clavix risk grade
regraded every trading dayIQV grades B, 72.5 of 100. Steadiest on Macro Resilience (63), most exposed on News Sentiment (40, fragile). 1 of the 4 weighted dimensions sit above the Life Sciences Tools & Services median. Ranks 11 of 19 in Life Sciences Tools & Services by Clavix score.
How rough the ride is
| IQV | Life Sciences Tools & Services median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.18 | 1.18 |
| Volatilityannualized | 29.4% | 29.4% |
| Max drawdown, past yearworst peak-to-trough fall | −35.9% | — |
| Typical daily movemedian absolute daily change | 1.15% | — |
| Days beyond ±3%of the last 252 sessions | 32 (13%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| IQV | Life Sciences Tools & Services median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.18 | 1.18 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 47% of 19 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Life Sciences Tools & Services names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| IQV | |
|---|---|
| 1 week | −4.5% |
| 1 month | −2.1% |
| Year to date | +14.6% |
| 1 year | +26.7% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| IQV | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 4 Aug |
| Average score0 most bearish, 100 most bullish | 62 |
| Bullish · bearisharticles above 60 · below 40 | 20 · 4 |
| Directionarticles whose tone is improving vs worsening | 20 ↑ 4 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 19 Life Sciences Tools & Services names Clavix covers; the tick is the sector median.
Growth
| IQV | |
|---|---|
| Revenue growthyear over year | +5.9% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Life Sciences Tools & Services median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openItaly's Data Protection Authority fined IQVIA Solutions Italy Srl €7 million after finding that data on roughly one million patients of 800 family doctors was not properly anonymized.
An article reviews IQVIA's business, noting that its large healthcare database, AI tools, and strong bookings in its research services support growth, while limited cash on hand and $14.1 billion in net debt are flagged as concerns.
IQVIA's large healthcare database, AI tools, and strong bookings for its research and development services support its growth, though the company carries low liquidity (easily accessible cash) and $14.1 billion in net debt.
A North Carolina Business Court judge said he was 'flummoxed' by IQVIA's argument against enforcing its own forum selection clause in a lawsuit over four top executives who left for a competitor.
UBS Group raised its rating on IQVIA to "strong-buy" in a research report on Wednesday.
Nearest peers by size
Life Sciences Tools & Services| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| ILMN | Illumina Inc | B- | $41.23B | 49.97 | 1.43 | Compare |
| WAT | Waters Corp | B+ | $43.82B | 258.85 | 1.16 | Compare |
| A | Agilent Technologies Inc | B | $47.30B | 32.85 | 1.25 | Compare |
| MTD | Mettler-toledo International Inc | B+ | $29.78B | 32.88 | 1.20 | Compare |
| WST | West Pharmaceutical Services Inc | A- | $23.90B | 46.80 | 1.15 | Compare |
| RVTY | Revvity Inc | B | $16.91B | 71.18 | 1.09 | Compare |
| MEDP | Medpace Holdings Inc | B | $16.73B | 34.04 | 1.11 | Compare |
| CRL | Charles River Laboratories International Inc | B- | $13.85B | — | 1.38 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.